Canurta Therapeutics

Canurta Therapeutics is a biotechnology company focused on developing a new class of anti-inflammatory therapeutics derived from rare hemp polyphenols, specifically cannflavins. The company utilizes a proprietary extraction and stabilization platform to harness these compounds, which demonstrate significant potency in inhibiting pro-inflammatory mediators. Their primary research targets neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer's, and Parkinson's, where neuroinflammation plays a critical role. By optimizing the bioavailability of these natural molecules, Canurta aims to provide safer and more effective treatments for chronic inflammatory conditions. The company's lead program, CT-001, is currently in pre-clinical development for the treatment of ALS. Canurta's approach leverages the unique properties of Cannflavin A and B, which are known to be significantly more potent than traditional NSAIDs like aspirin.